menu
    • menu
    [{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"SporeGen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"SPOR-COV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Destiny Pharma \/ SporeGen","highestDevelopmentStatusID":"4","companyTruncated":"Destiny Pharma \/ SporeGen"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"NTCD-M3","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"NTCD-M3","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Liquid","sponsorNew":"Destiny Pharma \/ Sebela Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Sebela Pharmaceuticals Inc"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"finnCap Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"NTCD-M3","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Destiny Pharma \/ finnCap Limited","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ finnCap Limited"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"SporeGen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Bacillus Bacteria","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Destiny Pharma \/ SporeGen","highestDevelopmentStatusID":"4","companyTruncated":"Destiny Pharma \/ SporeGen"}]

    Find Clinical Drug Pipeline Developments & Deals by Destiny Pharma

    Menu

    Destiny Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Bacteria

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : SporeGen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Destiny Pharma and SporeGen® Announce Update from Research Collaboration Under Innovate UK Grant Award to Dev...

                            Details : SPOR COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. It is being developed for for COVID-19 and Influenza.

                            Brand Name : SPOR-COV

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 02, 2023

                            Lead Product(s) : Bacillus Bacteria

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : SporeGen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Sebela Pharmaceuticals

                            Deal Size : $570.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Agreement with Sebela Pharmaceuticals for NTCD-M3

                            Details : Under the terms of the deal, Sebela will lead the future clinical development and commercialisation activities of NTCD-M3 in North America. NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. di...

                            Brand Name : NTCD-M3

                            Molecule Type : Large molecule

                            Upfront Cash : $1.0 million

                            February 24, 2023

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Sebela Pharmaceuticals

                            Deal Size : $570.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : finnCap Limited

                            Deal Size : $9.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Destiny Pharma Announces Fundraising Upto £8 Million

                            Details : The net proceeds of the Fundraising will allow the Company to complete final Phase 3 clinical trial preparation for NTCD-M3, Destiny pharma’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence.

                            Brand Name : NTCD-M3

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 24, 2023

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : finnCap Limited

                            Deal Size : $9.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel

                            Details : XF-73 reduced the mean nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery in the micro-ITT (Intend to Treat) population, a statistically highly significant result.

                            Brand Name : XF-73

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 29, 2021

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Destiny Pharma Completes Phase 2b Clinical Trial of XF-73 Patient Recruitment

                            Details : XF-73 is a first-in-class drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of postsurgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus.

                            Brand Name : XF-73

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2021

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Update On the Recently Acquired NTCD-M3 Programme

                            Details : Destiny Pharma reported that it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the prevention of C. difficile infection (CDI) recurrence.

                            Brand Name : NTCD-M3

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 22, 2020

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPOR-COV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : SporeGen

                            Deal Size : $1.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SporeGen® Announces Collaboration with Destiny Pharma Supported by an Innovate UK grant award for a Preventat...

                            Details : Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.

                            Brand Name : SPOR-COV

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 08, 2020

                            Lead Product(s) : SPOR-COV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : SporeGen

                            Deal Size : $1.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Destiny Pharma’s Novel Antibiotic Asset XF-73 Clears Safety Review

                            Details : Positive interim safety review has been completed by an Independent Data Monitoring Committee (IDMC) of the Company’s ongoing Phase 2b study of its lead asset XF-73 in the prevention of post-surgical bacterial infections.

                            Brand Name : XF-73

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 11, 2020

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Destiny Pharma Provides Update on its Phase 2b Clinical Study of XF-73

                            Details : Destiny Pharma agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value. The study is evaluating XF-73 for the prevention of post-surgical hospital infections caused by Staphylococcus aureus bacteria, su...

                            Brand Name : XF-73

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 27, 2020

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Independent Expert Review of Data Supports the Potential of XF-73 to Address Antimicrobial Resistance

                            Details : Data published to date support the unique target profile of XF-73 and its potential to address the threat of AMR.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 04, 2020

                            Lead Product(s) : Exeporfinium chloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth